PubMed:29630438 JSONTXT

{"project":"Zierdiyeerkenaili_800_3","denotations":[{"id":"T1","span":{"begin":50,"end":53},"obj":"CI"},{"id":"T2","span":{"begin":207,"end":210},"obj":"CI"},{"id":"T3","span":{"begin":601,"end":604},"obj":"CI"},{"id":"T4","span":{"begin":755,"end":758},"obj":"CI"},{"id":"T5","span":{"begin":1485,"end":1488},"obj":"CI"},{"id":"T6","span":{"begin":1700,"end":1703},"obj":"CI"},{"id":"T7","span":{"begin":1772,"end":1775},"obj":"CI"},{"id":"T8","span":{"begin":1942,"end":1945},"obj":"CI"},{"id":"T9","span":{"begin":2057,"end":2060},"obj":"CI"},{"id":"T10","span":{"begin":2162,"end":2165},"obj":"CI"},{"id":"T11","span":{"begin":54,"end":76},"obj":"CI"},{"id":"T12","span":{"begin":211,"end":233},"obj":"CI"},{"id":"T13","span":{"begin":605,"end":611},"obj":"CI"},{"id":"T16","span":{"begin":759,"end":765},"obj":"CI"},{"id":"T17","span":{"begin":1489,"end":1495},"obj":"CI"},{"id":"T18","span":{"begin":1704,"end":1710},"obj":"CI"},{"id":"T19","span":{"begin":1776,"end":1782},"obj":"CI"},{"id":"T20","span":{"begin":1946,"end":1952},"obj":"CI"},{"id":"T21","span":{"begin":2061,"end":2067},"obj":"CI"},{"id":"T22","span":{"begin":2166,"end":2172},"obj":"CI"},{"id":"T23","span":{"begin":536,"end":559},"obj":"CI"},{"id":"T24","span":{"begin":561,"end":564},"obj":"CI"},{"id":"T25","span":{"begin":1213,"end":1216},"obj":"CI"},{"id":"T26","span":{"begin":1658,"end":1661},"obj":"CI"},{"id":"T27","span":{"begin":2228,"end":2231},"obj":"CI"},{"id":"T28","span":{"begin":235,"end":244},"obj":"CI"},{"id":"T29","span":{"begin":791,"end":794},"obj":"CI"},{"id":"T30","span":{"begin":1402,"end":1405},"obj":"CI"},{"id":"T31","span":{"begin":1726,"end":1729},"obj":"CI"},{"id":"T32","span":{"begin":1987,"end":1990},"obj":"CI"},{"id":"T33","span":{"begin":769,"end":789},"obj":"CI"},{"id":"T34","span":{"begin":796,"end":805},"obj":"CI"},{"id":"T35","span":{"begin":566,"end":573},"obj":"CI"},{"id":"T36","span":{"begin":934,"end":942},"obj":"CI"},{"id":"T37","span":{"begin":1015,"end":1023},"obj":"CI"},{"id":"T38","span":{"begin":1333,"end":1341},"obj":"CI"},{"id":"T39","span":{"begin":846,"end":932},"obj":"CI"},{"id":"T40","span":{"begin":1202,"end":1209},"obj":"CI"},{"id":"T41","span":{"begin":512,"end":519},"obj":"CI"},{"id":"T42","span":{"begin":1321,"end":1328},"obj":"CI"},{"id":"T43","span":{"begin":1620,"end":1627},"obj":"CI"},{"id":"T44","span":{"begin":1907,"end":1914},"obj":"CI"},{"id":"T45","span":{"begin":1958,"end":1965},"obj":"CI"},{"id":"T46","span":{"begin":2196,"end":2203},"obj":"CI"},{"id":"T47","span":{"begin":424,"end":510},"obj":"CI"},{"id":"T48","span":{"begin":2205,"end":2223},"obj":"CI"},{"id":"T49","span":{"begin":948,"end":981},"obj":"CI"},{"id":"T50","span":{"begin":105,"end":150},"obj":"CI"}],"text":"Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial.\nThe RTS,S/AS01 malaria vaccine (Mosquirix) reduces the incidence of Plasmodium falciparum malaria and is intended for routine administration to infants in Sub-Saharan Africa. We evaluated the immunogenicity and safety of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV; Synflorix) and human rotavirus vaccine (HRV; Rotarix) when co-administered with RTS,S/AS01 ( www.clinicaltrials.gov NCT01345240) in African infants. 705 healthy infants aged 8-12 weeks were randomized to receive three doses of either RTS,S/AS01 or licensed hepatitis B (HBV; Engerix B) vaccine (control) co-administered with diphtheria-tetanus-acellular pertussis-Haemophilus influenzae type-b-conjugate vaccine (DTaP/Hib) and trivalent oral poliovirus vaccine at 8-12-16 weeks of age, because DTaP/Hib was not indicated before 8 weeks of age. The vaccination schedule can still be considered broadly applicable because it was within the age range recommended for EPI vaccination. PHiD-CV or HRV were either administered together with the study vaccines, or after a 2-week interval. Booster doses of PHiD-CV and DTaP/Hib were administered at age 18 months. Non-inferiority of anti-HBV surface antigen antibody seroprotection rates following co-administration with RTS,S/AS01 was demonstrated compared to the control group (primary objective). Pre-specified non-inferiority criteria were reached for PHiD-CV (for 9/10 vaccine serotypes), HRV, and aP antigens co-administered with RTS,S/AS01 as compared to HBV co-administration (secondary objectives). RTS,S/AS01 induced a response to circumsporozoite protein in all groups. Pain and low grade fever were reported more frequently in the PHiD-CV group co-administered with RTS,S/AS01 than PHiD-CV co-administered with HBV. No serious adverse events were considered to be vaccine-related. RTS,S/AS01 co-administered with pediatric vaccines had an acceptable safety profile. Immune responses to RTS,S/AS01 and to co-administered PHiD-CV, pertussis antigens and HRV were satisfactory."}

{"project":"yaoziqian_800_3","denotations":[{"id":"T12","span":{"begin":105,"end":150},"obj":"CI"},{"id":"T14","span":{"begin":235,"end":244},"obj":"CI"},{"id":"T15","span":{"begin":424,"end":510},"obj":"CI"},{"id":"T16","span":{"begin":512,"end":519},"obj":"CI"},{"id":"T17","span":{"begin":1202,"end":1209},"obj":"CI"},{"id":"T18","span":{"begin":1321,"end":1328},"obj":"CI"},{"id":"T19","span":{"begin":1620,"end":1627},"obj":"CI"},{"id":"T20","span":{"begin":1907,"end":1914},"obj":"CI"},{"id":"T21","span":{"begin":1958,"end":1965},"obj":"CI"},{"id":"T22","span":{"begin":2196,"end":2203},"obj":"CI"},{"id":"T25","span":{"begin":791,"end":794},"obj":"CI"},{"id":"T26","span":{"begin":1402,"end":1405},"obj":"CI"},{"id":"T27","span":{"begin":1726,"end":1729},"obj":"CI"},{"id":"T28","span":{"begin":1987,"end":1990},"obj":"CI"},{"id":"T29","span":{"begin":846,"end":932},"obj":"CI"},{"id":"T30","span":{"begin":934,"end":942},"obj":"CI"},{"id":"T31","span":{"begin":1015,"end":1023},"obj":"CI"},{"id":"T32","span":{"begin":1333,"end":1341},"obj":"CI"},{"id":"T33","span":{"begin":50,"end":53},"obj":"CI"},{"id":"T34","span":{"begin":207,"end":210},"obj":"CI"},{"id":"T35","span":{"begin":601,"end":604},"obj":"CI"},{"id":"T36","span":{"begin":755,"end":758},"obj":"CI"},{"id":"T37","span":{"begin":1485,"end":1488},"obj":"CI"},{"id":"T38","span":{"begin":1700,"end":1703},"obj":"CI"},{"id":"T39","span":{"begin":1772,"end":1775},"obj":"CI"},{"id":"T40","span":{"begin":1942,"end":1945},"obj":"CI"},{"id":"T41","span":{"begin":2057,"end":2060},"obj":"CI"},{"id":"T42","span":{"begin":2162,"end":2165},"obj":"CI"},{"id":"T43","span":{"begin":54,"end":76},"obj":"CI"},{"id":"T44","span":{"begin":211,"end":233},"obj":"CI"},{"id":"T45","span":{"begin":605,"end":611},"obj":"CI"},{"id":"T48","span":{"begin":759,"end":765},"obj":"CI"},{"id":"T49","span":{"begin":1489,"end":1495},"obj":"CI"},{"id":"T50","span":{"begin":1704,"end":1710},"obj":"CI"},{"id":"T51","span":{"begin":1776,"end":1782},"obj":"CI"},{"id":"T52","span":{"begin":1946,"end":1952},"obj":"CI"},{"id":"T53","span":{"begin":2061,"end":2067},"obj":"CI"},{"id":"T54","span":{"begin":2166,"end":2172},"obj":"CI"},{"id":"T55","span":{"begin":536,"end":559},"obj":"CI"},{"id":"T56","span":{"begin":561,"end":564},"obj":"CI"},{"id":"T57","span":{"begin":1213,"end":1216},"obj":"CI"},{"id":"T58","span":{"begin":1658,"end":1661},"obj":"CI"},{"id":"T59","span":{"begin":2228,"end":2231},"obj":"CI"},{"id":"T60","span":{"begin":566,"end":573},"obj":"CI"},{"id":"T61","span":{"begin":796,"end":805},"obj":"CI"},{"id":"T62","span":{"begin":2205,"end":2223},"obj":"CI"},{"id":"T63","span":{"begin":769,"end":789},"obj":"CI"},{"id":"T64","span":{"begin":948,"end":981},"obj":"CI"}],"text":"Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial.\nThe RTS,S/AS01 malaria vaccine (Mosquirix) reduces the incidence of Plasmodium falciparum malaria and is intended for routine administration to infants in Sub-Saharan Africa. We evaluated the immunogenicity and safety of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV; Synflorix) and human rotavirus vaccine (HRV; Rotarix) when co-administered with RTS,S/AS01 ( www.clinicaltrials.gov NCT01345240) in African infants. 705 healthy infants aged 8-12 weeks were randomized to receive three doses of either RTS,S/AS01 or licensed hepatitis B (HBV; Engerix B) vaccine (control) co-administered with diphtheria-tetanus-acellular pertussis-Haemophilus influenzae type-b-conjugate vaccine (DTaP/Hib) and trivalent oral poliovirus vaccine at 8-12-16 weeks of age, because DTaP/Hib was not indicated before 8 weeks of age. The vaccination schedule can still be considered broadly applicable because it was within the age range recommended for EPI vaccination. PHiD-CV or HRV were either administered together with the study vaccines, or after a 2-week interval. Booster doses of PHiD-CV and DTaP/Hib were administered at age 18 months. Non-inferiority of anti-HBV surface antigen antibody seroprotection rates following co-administration with RTS,S/AS01 was demonstrated compared to the control group (primary objective). Pre-specified non-inferiority criteria were reached for PHiD-CV (for 9/10 vaccine serotypes), HRV, and aP antigens co-administered with RTS,S/AS01 as compared to HBV co-administration (secondary objectives). RTS,S/AS01 induced a response to circumsporozoite protein in all groups. Pain and low grade fever were reported more frequently in the PHiD-CV group co-administered with RTS,S/AS01 than PHiD-CV co-administered with HBV. No serious adverse events were considered to be vaccine-related. RTS,S/AS01 co-administered with pediatric vaccines had an acceptable safety profile. Immune responses to RTS,S/AS01 and to co-administered PHiD-CV, pertussis antigens and HRV were satisfactory."}